| Previous Close | 0.4078 |
| Open | 0.4290 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3958 - 0.4290 |
| 52 Week Range | 0.1200 - 0.7200 |
| Volume | 786,526 |
| Avg. Volume | 1,005,488 |
| Market Cap | 130.089M |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0490 |
| Earnings Date | May 31, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an agreement with the University of Health Sciences Antigua (“UHSA”) to collaborate on utilizing Revive’s novel psychedelic-assisted therapies and pioneering the clinical research and developme
- GlobeNewswire
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that Derrick Welsh, COO of Psilocin Pharma Corp., a division of the Company, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. The corporate presentation
- GlobeNewswire
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a memorandum of understanding dated June 7, 2021 with Supriya Lifescience Ltd. (“Supriya”), a specialty pharmaceutical company based in India, to pursue manufacturing of the API, conducting cli
